Breast Neoplasms Clinical Trials

119 recruiting

Breast Neoplasms Trials at a Glance

128 actively recruiting trials for breast neoplasms are listed on ClinicalTrialsFinder across 6 cities in 53 countries. The largest study group is Not Applicable with 41 trials, with the heaviest enrollment activity in Houston, Madrid, and Guangzhou. Lead sponsors running breast neoplasms studies include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Merck Sharp & Dohme LLC, and Eli Lilly and Company.

Browse breast neoplasms trials by phase

Treatments under study

About Breast Neoplasms Clinical Trials

Looking for clinical trials for Breast Neoplasms? There are currently 119 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 128 trials

Recruiting
Phase 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms
BioNTech SE558 enrolled83 locationsNCT07173751
Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting

PREgnancy and FERtility Registry

Breast NeoplasmsPregnancyFertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy1,000 enrolled23 locationsNCT02895165
Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 1Phase 2

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Breast CancerBreast Neoplasms
Pfizer100 enrolled166 locationsNCT06966453
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354
Recruiting
Not Applicable

Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery

Breast Neoplasms
Fondazione Policlinico Universitario Campus Bio-Medico155 enrolled1 locationNCT06608446
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled28 locationsNCT07114601
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Not Applicable

Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer

Breast CancerBreast Neoplasms
European University Miguel de Cervantes66 enrolled2 locationsNCT07467824
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Not Applicable

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc.725 enrolled39 locationsNCT07214532
Recruiting

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

Breast Neoplasms
Spanish Breast Cancer Research Group1,867 enrolled40 locationsNCT02819882
Recruiting

DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes

Breast Neoplasms
Hubei Cancer Hospital30 enrolled1 locationNCT07263347
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Breast NeoplasmsAbemaciclibHormone Receptor-Positive Breast Cancer+4 more
Hubei Cancer Hospital60 enrolled1 locationNCT07264998
Recruiting
Phase 2

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Triple Negative Breast Neoplasms
Universitaire Ziekenhuizen KU Leuven53 enrolled6 locationsNCT06365788